Drug Target Review

OCTOBER 26, 2023

1 Adeno-associated virus (AAV) vectors are the leading platform for in vivo gene delivery for the treatment of various human diseases. 9 In addition, host immune responses further add to the complexity of developing cell-specific AAV capsids for clinical applications. Nature 578 , 229-236 (2020). References Doudna JA.

Engineering 105

Engineering Virus Therapies Immune Response 105

DrugBank

JULY 18, 2024

These epitopes serve as the primary targets for the immune system, triggering a response that protects against future infection. For instance, the influenza virus is notorious for its ability to undergo antigenic drift, accumulating mutations in its surface proteins that can render existing vaccines less effective. 

Vaccine 79

Vaccine Immune Response Clinical Trials Disease 79

PLOS: DNA Science

MAY 16, 2024

A Novel Virus Appears In retrospect, everything unfolded with astonishing speed. A few days after New Years, 2020, I heard BBC News report the first cases, in China. Whenever and wherever the virus emerged, CDC officially alerted clinicians to the new, deadly respiratory illness on January 8, 2020.

Virus 97

Virus DNA RNA Vaccine 97

The Pharma Data

JULY 15, 2021

Antibody and T-cell immune responses strong and stable at eight months after immunization Demonstrated neutralizing antibody activity against the Delta variant (B.1.617.2) of Beth Israel Deaconess Medical Center suggest maturation of B-cell response without further boosting. 1.1.7), Beta (B.1.351), 1.351), Gamma (P.1),

Immune Response 52

Immune Response Vaccine Clinical Trials FDA 52

The Pharma Data

DECEMBER 7, 2020

7, 2020 — Scientists say they may be getting closer to creating a universal flu vaccine. In an early-stage clinical trial with 65 volunteers in the United States, an experimental vaccine triggered strong immune responses to a wide range of flu virus strains and subtypes. © 2020 HealthDay. MONDAY, Dec.

Vaccine 52

Vaccine Immune Response Virus Clinical Trials 52

The Pharma Data

DECEMBER 31, 2020

31, 2020 — Blood vessel damage and inflammation in the brains of deceased COVID-19 patients suggest the damage is not caused by the virus, but the body’s immune response to it. The spots were surrounded by T cells — signs of an immune response. © 2020 HealthDay. Posted: December 2020.

Immune Response 52

Immune Response Virus Doctors Research 52

The Pharma Data

DECEMBER 31, 2020

Monthly News Roundup – December 2020. The messenger RNA (mRNA) vaccines encode a form of the spike (S) protein of SARS-CoV-2 virus. The vaccine teaches the cells to make a piece of the spike protein, which triggers an immune response to help prevent illness if later exposed to the virus. Professional.

FDA Approval 52

FDA Approval Vaccine FDA Treatment 52

NIH Director's Blog: Drug Development

JUNE 30, 2020

A major one is: just how well do those particular antibodies neutralize the virus to fight off the infection and help someone recover from COVID-19? Fortunately, most people get better—but should the typical antibody response take the credit? Not surprisingly, all volunteers had produced antibodies in response to the virus.

Immune Response 52

Immune Response Virus Vaccine Research 52

The Pharma Data

MARCH 3, 2022

If approved by the FDA, this maternal immunization has the potential to be the first vaccine candidate to help protect infants in their vulnerable first months of life from disease caused by this highly-contagious virus. Burden of RSV RSV is a contagious virus and a common cause of respiratory illness. Pfizer Inc.

Virus 52

Virus Vaccine Clinical Trials Trials 52

The Pharma Data

NOVEMBER 16, 2020

16, 2020 — Scientists are reporting early success with an experimental herpes vaccine that uses a genetically modified version of the virus. The gene edit prevents the virus from performing its normal evasive maneuver: hiding out in nervous system cells in order to elude the immune system. MONDAY, Nov.

Vaccine 52

Vaccine Immune Response Virus Clinical Trials 52

The Pharma Data

NOVEMBER 18, 2020

18, 2020 — Children should be included in clinical trials for a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine at the earliest stages, according to a letter from the president of the American Academy of Pediatrics (AAP), on behalf of more than 67,000 pediatricians and pediatric medical and surgical subspecialists. .”

Vaccine 52

Vaccine Trials Immune Response Virus 52

NIH Director's Blog: Drug Development

MARCH 18, 2021

With support from a 2020 NIH Director’s Pioneer Award, Veesler will study members of the order Chiroptera. These days, the Veesler lab has been hard at work to understand SARS-CoV-2 and the human immune response to the virus. 2020 Apr 16;181(2):281-292.e6. Or, more colloquially, bats.

Virus 52

Virus Immune Response Clinical Trials Treatment 52

The Pharma Data

DECEMBER 3, 2020

4, 2020 08:00 UTC. Strong Th1 cell-mediated immune responses were also observed for the vaccine candidates with either adjuvant. A global Phase 2/3 efficacy study of the S-Trimer vaccine candidate in combination with GSK’s pandemic adjuvant system is expected to begin in December 2020. CHENGDU, China.–(

Vaccine 52

Vaccine Immune Response Virus RNA 52

The Pharma Data

JUNE 25, 2021

The outcome confirms that only one single case was attributable to the original SARS-CoV-2 virus. “In addition, the variant-rich environment underlines the importance of developing next-generation vaccines as new virus variants continue to emerge.” More than half of the cases (57%) were caused by Variants of Concern.

Vaccine 52

Vaccine Trials Immune Response Virus 52

The Pharma Data

DECEMBER 16, 2020

16, 2020 (GLOBE NEWSWIRE) — Novavax , Inc. Currently in Phase 3 clinical testing in the United Kingdom for the prevention of COVID-19, NVX-CoV2373 is a recombinant protein vaccine adjuvanted with Novavax’ proprietary Matrix-M to enhance the immune response. GAITHERSBURG, Md., About Novavax. Novavax, Inc.?(Nasdaq:

Vaccine 52

Vaccine Government Immune Response Clinical Trials 52

Creative Biolabs

JULY 12, 2020

Professor Florian Klein, the paper’s corresponding author, explained, “our goal is to better understand the immune response to SARS-CoV-2 and to identify highly potent antibodies that can be used to prevent and treat COVID-19.” They are expected to enter clinical development later this year.

Immune Response 52

Immune Response Laboratories Clinical Trials Clinical Development 52

The Pharma Data

DECEMBER 22, 2020

22, 2020 — For Americans who are worried about the new coronavirus variant that is circulating in Britain, experts in the United States urge everyone to stay calm. “But again, the low mutation rate makes the adaptation of this virus to a vaccine less likely.” ” © 2020 HealthDay. TUESDAY, Dec.

Virus 52

Virus Vaccine Immune Response Treatment 52

The Pharma Data

OCTOBER 21, 2020

22, 2020 (GLOBE NEWSWIRE) — Replimune Group, Inc. The offering is expected to close on October 26, 2020, subject to the satisfaction of customary closing conditions. BOSTON, Oct. Morgan Securities LLC, SVB Leerink LLC and Barclays Capital Inc. are acting as joint book-running managers for the offering.

Immune Response 40

Immune Response Clinical Trials Therapies Production 40

The Pharma Data

JUNE 30, 2021

For their remarkable scientific contributions, doctoral student Julia Klaus, Zurich University VetSuisse Faculty, and Dr Yasmin Parr from the MRC-University of Glasgow, Centre for Virus Research, have received the 2021 ABCD Young Scientist Award. To foster young talent development in the feline health research community.

Immune Response 52

Immune Response Virus Disease Doctors 52

The Pharma Data

JUNE 26, 2021

The trial will evaluate the safety and immunogenicity of a monovalent flu vaccine candidate coding for the hemagglutinin protein of the A/H3N2 strain of the influenza virus. Preclinical results were shared previously at the 8 th annual mRNA Healthcare Conference in November 2020.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

DECEMBER 11, 2020

11, 2020 — More than 15 million Americans have been infected by the COVID-19 virus, and many may be questioning whether they need to receive one of the two coronavirus vaccines now on the verge of approval from U.S. © 2020 HealthDay. Posted: December 2020. FRIDAY, Dec. regulators. Short answer: Yes. Source link.

Vaccine 52

Vaccine Immune Response Virus Trials 52

The Pharma Data

DECEMBER 20, 2020

BT-001 is a best-in-class oncolytic Vaccinia virus. platform and its patented large-capacity VV cop TK-RR- oncolytic virus, which has been engineered to encode both a Treg-depleting human recombinant anti-CTLA4 antibody generated by BioInvent’s proprietary n-CoDeR ® /F.I.R.S.T LUND, Sweden and STRASBOURG, France , Dec.

Virus 40

Virus Trials Clinical Trials Clinical Development 40

The Pharma Data

NOVEMBER 9, 2020

09, 2020 (GLOBE NEWSWIRE) — Novavax, Inc. NVX-CoV2373 is a vaccine candidate engineered from the genetic sequence of SARS-CoV-2, the virus that causes COVID-19 disease. is undertaking clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. Posted: November 2020.

Vaccine 52

Vaccine FDA Clinical Trials Immune Response 52

The Pharma Data

DECEMBER 31, 2020

31, 2020 — Folks who contract COVID-19 can expect to gain some durable immunity against future infection, according to a new study of memory cells within the immune systems of coronavirus patients. ” © 2020 HealthDay. Posted: December 2020. THURSDAY, Dec. All rights reserved. Source link.

Vaccine 52

Vaccine Virus Immune Response Disease 52

The Pharma Data

DECEMBER 11, 2020

The University of Oxford has regularly appeared in our updates since July 2020, as its team of researchers leads an ongoing clinical trial for the Covid-19 vaccine. More recently, the university has released news of its collaboration with Thermo Fisher Scientific as it looks to discover an immune Covid-19 response pre- and post-vaccination.

Vaccine 52

Vaccine Immune Response Pharma Companies Virus 52

NIH Director's Blog: Drug Development

MAY 21, 2020

B38 blocks SARS-CoV-2 from binding to the ACE2 receptor (light pink) of a human cell, ACE2 is what the virus uses to infect cells. References : [1] Humoral immune response and prolonged PCR positivity in a cohort of 1343 SARS-CoV 2 patients in the New York City region. Preprint Posted May 5, 2020. [2]

Virus 52

Virus Vaccine Laboratories Small Molecule 52

The Pharma Data

MAY 17, 2021

Sanofi and GlaxoSmithKline (GSK) have reemerged as COVID-19 vaccine contenders after their reformulated candidate delivered a strong immune response across all age groups in a phase 2 study. 14, 2020 ). 2 virus and the variant first identified in South Africa. Although wealthy territories like the U.S.,

Vaccine 40

Vaccine Immune Response RNA Virus 40

The Pharma Data

NOVEMBER 24, 2020

24, 2020 – At least thee new COVID-19 vaccine candidates are already in the pipeline, will a roll-out expected early in the new year. “These are immune responses, so if you feel something after vaccination, you should expect to feel that. Vaccines work to fight disease by producing an immune response within the body.

Vaccine 52

Vaccine Virus Immune Response Hospitals 52

The Pharma Data

FEBRUARY 22, 2021

New Phase 2 study assesses potential for refined antigen formulation to achieve optimal immune response, including in older adults. Sanofi and GSK’s adjuvanted recombinant protein-based COVID-19 vaccine candidate was selected in July 2020 by the U.S. In parallel, development work on new SARS-CoV-2 variants underway.

Vaccine 52

Vaccine Immune Response Trials Clinical Trials 52

The Pharma Data

SEPTEMBER 17, 2020

The new Elecsys Anti-SARS-CoV-2 S test can quantitatively measure the level of antibodies against SARS-CoV-2 in patients who have been exposed to the virus. Basel, 18 September 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of its Elecsys® Anti-SARS-CoV-2 S antibody test for markets accepting the CE Mark.

Vaccine 52

Vaccine Virus Clinical Trials Immune Response 52

The Pharma Data

SEPTEMBER 2, 2021

Respiratory syncytial virus (RSV) is a common and pervasive cause of acute respiratory illness. 2,3 The virus is highly contagious and affects the lungs and airways. RSV is a significant cause of severe respiratory disease in older adults, and it can cause disability and death. Burden of RSV.

Clinical Trials 52

Clinical Trials Trials Vaccine Virus 52

The Pharma Data

JANUARY 4, 2021

Dr. Anthony Fauci said Sunday that the country has fallen far short of its goal of vaccinating 20 million Americans by the end of 2020. “There is a path forward if you can show that two lower doses yield a similar immune response,” Dean said. By Saturday, only 4.2

Vaccine 52

Vaccine Immune Response Virus Hospitals 52

The Pharma Data

OCTOBER 28, 2020

28, 2020 /PRNewswire/ — . “We continue to see the strongest effects in patients who are most at risk for poor outcomes due to high viral load, ineffective antibody immune response at baseline, or pre-existing risk factors. TARRYTOWN, N.Y. , Regeneron has shared these results with the U.S. Yancopoulos , M.D.,

Virus 40

Virus Trials Clinical Trials Production 40

The Pharma Data

DECEMBER 9, 2020

9, 2020 — COVID-19 can cause a wide range of neurological complications, even in patients who are not critically ill, a new study shows. Some problems, she said, are related to an overactive immune response — such as Guillain-Barre syndrome, where the immune system attacks the body’s nerves.

Hospitals 52

Hospitals Doctors Immune Response Virus 52

NIH Director's Blog: Drug Development

OCTOBER 27, 2020

Science, 2020 One way to fight COVID-19 is with drugs that directly target SARS-CoV-2, the novel coronavirus that causes the disease. Another promising strategy is drugs that target the proteins within human cells that the virus needs to infect, multiply, and spread. 2020 Oct 15:eabe9403. Credit: DE Gordon et al.,

Drug Development 52

Drug Development Drugs Virus Science 52

The Pharma Data

AUGUST 28, 2020

Oxford coronavirus vaccine triggers immune response. UK signs deals for 90 million virus vaccine doses. The UK remains under the jurisdiction of the European Medicines Agency and its licensing scheme until the end of the Brexit transition period on 31 December 2020.

Vaccine 52

Vaccine Immune Response Nurses Government 52

The Pharma Data

NOVEMBER 23, 2020

Once injected, the cells churn out the spike protein, triggering the body’s immune system to recognize the virus. Likely EUA Date: December 10, 2020. Likely EUA Date: December 10, 2020. After vaccination, the cells produce the spike protein, stimulating the immune system to attack the SARS-CoV-2 virus.

Vaccine 52

Vaccine Virus Immune Response Trials 52